Human OPA3 CRISPR gRNA in Lenti Particles
This is a Optic Atrophy 3 (Autosomal Recessive, with Chorea and Spastic Paraplegia) plasmid with gRNA insert cloned into Lentiviral VectorpLenti-U6-sgRNA-PGK-Neo. Insert length: not_set. Stable, Transient expression. Suitable for PExp and GEEN.
Bacterial selection: Ampicillin.
Catalog No. ABIN5155607
$693.75
Plus shipping costs $50.00, if applicable $20.00 dry ice
300 μL
Shipping to:
United States
Delivery in 31 to 41 Business Days
Quick Overview for Human OPA3 CRISPR gRNA in Lenti Particles (ABIN5155607)
Gene
OPA3
(Optic Atrophy 3 (Autosomal Recessive, with Chorea and Spastic Paraplegia) (OPA3))
Application
Protein Expression (PExp), Genome Editing with Engineered Nucleases (GEEN)
Insert
gRNA
Vector
Lentiviral Vector
Vector Backbone
pLenti-U6-sgRNA-PGK-Neo
Promoter
U6 Promoter, PGK Promoter
Bacterial Resistance
Ampicillin
Expression Type
Stable, Transient
-
-
Species
- Human
-
Purpose
- Individual gRNA against OPA3 in Lentiviral Particles with a Titer of >1x10e7 IU/mL. (Cas9 required separately)
-
Sequence
- Sequence available upon placing order
-
Specificity
- GRNAs are designed for use with Cas9 Nuclease only.
-
Components
- Lentiviral particles with an individual gRNA (300 μL) for a specific sequence of OPA3
-
Selectable Marker
- Neomycin
-
-
-
-
Application Notes
- Recommended for quality control: Restriction Enzyme Digest and Sequencing
-
Restrictions
- For Research Use only
-
-
-
Format
- Viral Particles
-
Storage
- -80 °C
-
Expiry Date
- 12 months
-
-
- OPA3 (Optic Atrophy 3 (Autosomal Recessive, with Chorea and Spastic Paraplegia) (OPA3))
-
Alternative Name
- OPA3
-
NCBI Accession
- NM_001017989
Target
-
You are here:
